Verastem (VSTM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.31
- Estimate
- -$0.45
- Surprise
- +30.6%
- Revenue (period 2026-06-30)
- $40.1M
- Score at report (before → after)
- 5.4 → 5.3/10
Revenue source: mixed.
How the report landed
Verastem (VSTM) reported a narrower loss than forecast — diluted EPS of -$0.31 against the -$0.45 estimate (a 30.6% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (5.4/10) to Sell at 5.3/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates VSTM Sell at 5.5/10.
4 of the last 4 quarters beat the estimate; this quarter's +30.6% surprise compares with a +14.2% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Product: AVMAPKI FAKZYNJA CO-PACK
- Risk below floor (2.5 < 3.0)
- Momentum score 3.6/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.85
- Price target
- $12.83
- Stop
- $6.41
- Upside to target
- +87.3%
- Reward-to-risk
- 5.8:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
VSTM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $624.0M
- P/E (fwd)
- -9.2
- 52-week range
- $3.43–$11.25
- Off 52-week high
- 39.1%
- RSI (14)
- 68
- Volume vs avg
- 0.50×
- Score today
- 5.5/10